David Laplaud
David Laplaud, MD, PhD is an expert in Neurology at Centre Hospitalier Universitaire de Nantes (France). As of October 2026, ScienceLeadR ranks David Laplaud in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. David Laplaud has authored 362 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 11 of them ongoing. SLR score: 1,528 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Immunology - Public Health - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 362
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack. PMID 42798289 — multiple sclerosis, serum, probability, biomarkers, neuromyelitis optica, diagnosis, nervous system diseases | Eur J Neurol | 2026 | 0 |
| Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis. PMID 42596034 — sclerosis, multiple sclerosis, aged, therapeutics, nervous system diseases, infections | Ann Clin Transl Neurol | 2026 | 0 |
| A multi-outcome prognostic score for therapeutic responses in multiple sclerosis. PMID 42481360 — registries, sclerosis, multiple sclerosis, brain, multiple chronic conditions, therapeutics, wounds and injuries, neurology | Rev Neurol (Paris) | 2026 | 0 |
| Mapping of class II HLA restriction of SepSecS-specific CD4 T cell epitopes in autoimmune hepatitis. PMID 42398735 — cells, hepatitis, autoimmune, epitopes, algorithms, cell line, t-lymphocytes, epitopes, t-lymphocyte, autoantigens, hepatitis | JHEP Rep | 2026 | 0 |
| Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity. PMID 42377966 — cells, sclerosis, multiple sclerosis, blood, lymphocytes, brain, adaptive immunity, wounds and injuries, neurology, immunology | Brain | 2026 | 0 |
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 15
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Treatment in Patients with Multiple Sclerosis Previously Enrolled in a Genentech and or F Hoffmann La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program 2023-507633-21-01 — sclerosis, multiple sclerosis, therapeutics | Phase 3 | Not yet recruiting | 2024 |
| LONG TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS CONSONANCE EXTENSION STUDY 2024-516433-13-00 — safety | Phase 3 | Recruiting | 2024 |
| A Rollover Study to Evaluate the Long Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis 2023-505974-14-00 — sclerosis, multiple sclerosis, safety | Phase 3 | Active not recruiting | 2022 |
| PRIMUS Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis NCT07647952 — sclerosis, multiple sclerosis, multiple chronic conditions, decision support systems, clinical, therapeutics, software, multiple sclerosis, relapsing-remitting, medical devices | N/A | Not yet recruiting | 2026 |
| Disease Modifying Therapies Withdrawal in Inactive Relapsing remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS Therapies Withdrawal IN Relapsing Multiple Sclerosis) NCT06663189 — glatiramer acetate, depression, sclerosis, multiple sclerosis, quality of life, spinal cord, disability evaluation, dimethyl fumarate, acetates, aged, fumarates, therapeutics, random allocation, multiple sclerosis, relapsing-remitting, infections, spine | Phase 3 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map